Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.

By M. Crump, S. Neelapu, U. Farooq, E. Van Den Neste, J. Kuruvilla, J. Westin, B. Link, A. Hay, James R. Cerhan, Liting Zhu and 7 more. Blood, 2017

1,571 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. (2021, neutral): “Febrile neutropenia 4 (2) 4 (2) 46 (27) 46 (27)”
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. (2020, background): “3months among patients with refractory DLBCL, and only 20% of patients were alive at 2 years.(2) Although frontline anthracycline-based chemoimmunotherapy is curative for many patients,(3,4) only a small fraction with relapsed disease achieve prolonged disease-free survival with salvage chemotherapy”
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (2019, background): “However, prognosis is poor for most patients with R/R DLBCL who are ineligible for ASCT because of age, comorbidity, or inadequate response to salvage chemotherapy and for those who relapse after ASCT, with a median overall survival (OS) of approximately 6 months.(8) Currently, there is no standard ”